Published in J Urol on June 01, 2003
Laparoscopy and urologic oncology--I now pronounce you man and wife. J Urol (2003) 1.38
Re: Laparoscopic radical nephrectomy: incorporating the advantages of hand assisted and standard laparoscopy. J Urol (2003) 0.75
Strategies in the management of renal tumors amenable to partial nephrectomy. Surg Endosc (2008) 0.75
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol (2002) 3.06
Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol (2006) 3.02
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
General protein diffusion barriers create compartments within bacterial cells. Cell (2012) 2.48
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer (2002) 2.33
Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol (2007) 2.31
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology (2011) 2.12
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology (2011) 2.07
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology (2010) 2.04
Vaginal extraction of the intact specimen following laparoscopic radical nephrectomy. J Urol (2002) 2.03
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol (2008) 2.02
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys (2002) 2.01
Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate cancer. J Virol (2009) 2.00
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res (2003) 1.95
The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. Nat Rev Urol (2010) 1.94
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol (2008) 1.93
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology (2006) 1.75
Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol (2009) 1.73
Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology (2008) 1.71
Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.71
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys (2004) 1.64
Female sexual dysfunction: classification, pathophysiology, and management. Fertil Steril (2007) 1.62
Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol (2003) 1.59
Laparoscopic anatrophic nephrolithotomy: feasibility study in a chronic porcine model. J Urol (2003) 1.58
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies. Retrovirology (2010) 1.57
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Management of failed primary intervention for ureteropelvic junction obstruction: 12-year, single-center experience. Urology (2003) 1.56
Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology (2010) 1.53
Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. PLoS One (2011) 1.52
A multivariate analysis of risk factors associated with subcapsular hematoma formation following electromagnetic shock wave lithotripsy. J Urol (2004) 1.51
Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst (2009) 1.49
Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol (2008) 1.49
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet (2006) 1.46
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol (2007) 1.42
Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. Urology (2012) 1.42
Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer. BJU Int (2012) 1.41
Brachytherapy or surgery? A composite view. Oncology (Williston Park) (2009) 1.41
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) (2011) 1.38
Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. Urology (2005) 1.38
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int (2010) 1.37
Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol (2008) 1.35
In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS One (2012) 1.33
Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys (2005) 1.32
Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int (2008) 1.31
Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer (2009) 1.29
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
Retracted Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression. Dev Cell (2003) 1.28
Laparoscopic management of caliceal diverticular calculi. J Urol (2002) 1.27
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology (2004) 1.25
Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol (2004) 1.25
Fellowship training as a modifier of the surgical learning curve. Acad Med (2010) 1.24
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys (2005) 1.23
Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology (2004) 1.20
Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int (2011) 1.19
Association of Mycoplasma hominis infection with prostate cancer. Oncotarget (2011) 1.19
The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer (2002) 1.18
Pathologic stage migration has slowed in the late PSA era. Urology (2007) 1.17
Single access site laparoscopic radical nephrectomy: initial clinical experience. J Endourol (2008) 1.16
Finding help for sexual problems after prostate cancer treatment: a phone survey of men's and women's perspectives. Psychooncology (2003) 1.15
Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem (2002) 1.14
Aggressiveness of familial prostate cancer. J Clin Oncol (2006) 1.13
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol (2008) 1.13